Early schizophrenia: long-acting oral and injectable antipsychotics have similar efficacy

To remember

• Treatment with long-acting injectable antipsychotics (LPIs) does not appear to prevent more treatment discontinuations or offer an advantage over oral medications in patients with early-stage schizophrenia.

Why is this important?

• Discuss API antipsychotic therapy with patients to determine if the benefits (maintenance of cognitive function, reduction in suicides, decreased risk of rehospitalization) outweigh the need for monthly injections.